| First Author | Georgescu MM | Year | 2016 |
| Journal | Neoplasia | Volume | 18 |
| Issue | 8 | Pages | 512-23 |
| PubMed ID | 27566107 | Mgi Jnum | J:317011 |
| Mgi Id | MGI:6844286 | Doi | 10.1016/j.neo.2016.07.003 |
| Citation | Georgescu MM, et al. (2016) NHERF1/EBP50 Suppresses Wnt-beta-Catenin Pathway-Driven Intestinal Neoplasia. Neoplasia 18(8):512-23 |
| abstractText | NHERF1/EBP50, an adaptor molecule that interacts with beta-catenin, YAP, and PTEN, has been recently implicated in the progression of various human malignancies, including colorectal cancer. We report here that NHERF1 acts as a tumor suppressor in vivo for intestinal adenoma development. NHERF1 is highly expressed at the apical membrane of mucosa intestinal epithelial cells (IECs) and serosa mesothelial cells. NHERF1-deficient mice show overall longer small intestine and colon that most likely could be attributed to a combination of defects, including altered apical brush border of absorbtive IECs and increased number of secretory IECs. NHERF1 deficiency in Apc(Min/+) mice resulted in significantly shorter animal survival due to markedly increased tumor burden. This resulted from a moderate increase of the overall tumor density, more pronounced in females than males, and a massive increase in the number of large adenomas in both genders. The analysis of possible pathways controlling tumor size showed upregulation of Wnt-beta-catenin pathway, higher expression of unphosphorylated YAP, and prominent nuclear expression of cyclin D1 in NHERF1-deficient tumors. Similar YAP changes, with relative decrease of phosphorylated YAP and increase of nuclear YAP expression, were observed as early as the adenoma stages in the progression of human colorectal cancer. This study discusses a complex role of NHERF1 for intestinal morphology and presents indisputable evidence for its in vivo tumor suppressor function upstream of Wnt-beta-catenin and Hippo-YAP pathways. |
